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ABSTRACT
Bone is the most common site for distant spread of
breast cancer. Following a diagnosis of metastatic
bone disease, patients can suffer from significant mor-
bidity because of pain and skeletal related events
(SREs). Bisphosphonates are potent inhibitors of os-
teoclastic function and the mainstay of bone-directed
therapy for bone metastases. The aims of bisphos-
phonates are to prevent and delay SREs, to reduce bone
pain, and to improve quality of life. Bisphosphonate
therapy appears to have revolutionized treatment of
bone metastases, but bisphosphonate use has several
limitations. Those limitations include the high cost
of the agents and the need for return trips to the clinic
for intravenous treatment. Moreover, many uncertain-
ties surround bisphosphonate use—for example, the
timing of bisphosphonate initiation, the choice of bis-
phosphonate to use, the optimal duration of treatment,
and the appropriate means to identify patients who
will and will not benefit. In addition, potentially se-
rious adverse effects have been associated with bis-
phosphonate use—for example, renal toxicity,
gastrointestinal side effects, and osteonecrosis of the
jaw. The present review is intended as a primer for
oncology specialists who treat patients with bone
metastases secondary to breast cancer. It focuses on
bisphosphonate treatment guidelines, the evidence for
those guidelines, and a discussion of new therapeu-
tic agents. It also discusses the use of biochemical
markers of bone metabolism, which show promise
for predicting the risk of a patient’s developing a SRE
and of benefiting from bisphosphonate treatment.
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1. INTRODUCTION
Bone is the most common site of breast cancer recur-
rence 1,2. Despite modern cancer therapy, up to two
thirds of patients with bone metastasis will subse-
quently develop an skeletal-related event (SRE), de-
fined as any of pathologic fracture, a requirement for
surgical intervention and palliative radiotherapy to
bone lesions, hypercalcemia of malignancy, and spi-
nal cord compression. Not only are SREs associated
with significant morbidity, they also negatively af-
fect survival. Moreover, SREs are associated with loss
of mobility and social functioning, and reduction in
quality of life (QOL) 2.
Treatment of bone metastases ideally involves a
multidisciplinary team, including medical oncologists,
radiation oncologists, palliative care specialists, and
orthopedic surgeons. Systemic treatment aimed at
delaying the progression of bone metastases may in-
clude endocrine therapy, biologic agents, chemo-
therapy, and oral or intravenous bisphosphonate
therapy. New osteoclast inhibitors are currently under
investigation and may offer alternative treatment op-
tions for these patients in the future.
2. BISPHOSPHONATES
Bisphosphonates are an established standard of care
for patients with bone metastases. Table I reviews the
American Society of Clinical Oncology (ASCO) and
Cancer Care Ontario guidelines regarding bisphos-
phonate use in breast cancer patients with bone me-
tastases 3,4. Bisphosphonates are potent inhibitors of
osteoclast-mediated bone resorption through several
mechanisms, including induction of osteoclast apo-
ptosis, inhibition of osteoclast maturation and differ-
entiation, and reduced osteoclast activity 5. In
addition, bisphosphonates may act directly on tumour
cells by inducing apoptosis, inhibiting matrix
metalloproteinase 1, inhibiting angiogenesis, decreas-
ing adhesion of tumour cells within bone, and reduc-
ing levels of vascular endothelial growth factor 6.
2.1 Bisphosphonate Trials and Meta-analyses
The clinical benefits of bisphosphonate therapy in
secondary prophylaxis (that is, their use in patients
with breast cancer and established bone metastases)
have been demonstrated in a large number of pla-
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cebo-controlled trials and meta-analyses 7–12. As com-
pared with placebo, zoledronic acid, pamidronate,
clodronate, and ibandronate have all been shown to
reduce the risk of SREs and to increase time to first
SRE 8–19 (Table II).
A large meta-analysis encompassing eighteen
studies (five of which were conducted in breast can-
cer patients) indicated that, as compared with pla-
cebo, bisphosphonates significantly reduced the odds
ratios (ORs) for non-vertebral fractures [OR: 0.80; 95%
confidence interval (CI): 0.64 to 0.99], combined frac-
tures (OR: 0.75; 95% CI: 0.61 to 0.93), need for radio-
therapy (OR: 0.65; 95% CI: 0.54 to 0.79), need for
orthopedic surgery (OR: 0.59; 95% CI: 0.43 to 0.83),
and hypercalcemia (OR: 0.43; 95% CI: 0.29 to 0.63),
but not for spinal cord compression 20. Similarly, in a
Cochrane systemic review that included twenty-one
randomised studies involving bisphosphonate use
among breast cancer patients 21, nine of those studies
demonstrated a risk reduction (RR) of 17% (RR: 0.83;
95% CI: 0.78 to 0.89; p < 0.00001) for developing a
SRE with bisphosphonate use. Intravenous zoledronic
acid 4 mg was most effective in reducing the risk of
developing a SRE by 41% (RR: 0.59; 95% CI: 0.42 to
0.82). In seven of the studies, bisphosphonates, when
compared with placebo, significantly improved bone
pain 21.
The benefits of bisphosphonate therapy for vari-
ous SREs seem to be time-dependent; that is, the bis-
phosphonate must be given for at least 6 months
before an effect is seen on skeletal morbidity out-
comes and for at least 12 months before a reduction
in the need for orthopedic surgery becomes signifi-
cant 20. To date, treatment with bisphosphonate does
not appear to improve overall survival 21.
Results from clinical trials evaluating the analge-
sic properties of bisphosphonates vary considerably,
mostly because of differences in the patient popula-
tions and pain assessment scales 22,23. Placebo-con-
trolled trials of intravenous pamidronate, ibandronate,
and zoledronate have demonstrated improvement in
pain scores 7,12,22. Two published comparative trials
have reported an advantage for intravenous pamidro-
nate over oral clodronate in reducing metastatic bone
pain 24. A systemic review by Wong and Wiffen con-
cluded that although evidence supported bisphospho-
nate effectiveness in providing some pain relief for
bone metastasis, the data were insufficient to recom-
mend bisphosphonates as first-line therapy for me-
tastasis-related bone pain 25. New strategies of
bisphosphonate administration for bone pain are cur-
rently being explored 26.
Bisphosphonates are remarkably variable in struc-
ture and potency. The newer, nitrogen-containing
bisphosphonates such as ibandronate, pamidronate,
and zoledronic acid are several orders of magnitude
more potent than earlier-generation bisphosphonates
such as clodronate 27. Comparative bisphosphonate
trials have attempted to ascertain the superiority of
one bisphosphonate regimen over another, with end-
points being reduction in the incidence of SREs and
improvement of pain and QOL (Table III). One study
showed that pamidronate was superior to clodronate
with regard to pain (p < 0.01) and improvement in
biochemical markers of bone turnover 24. Another trial
demonstrated the superiority of zoledronic acid (4 mg
intravenously over 15 minutes) over pamidronate
(90 mg intravenously over 2 hours); patients treated
with zoledronic acid had an increased time to first
SRE (p = 0.013) and fewer SREs (p = 0.58) 29. In that
TABLE I American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) guidelines for bisphosphonate (BP) use in bone-
metastatic disease in breast cancer patients 3,4
ASCO (2003 update) CCO (2004 update)
Recommended BP Intravenous pamidronate or zoledronic acid. Oral clodronate, intravenous pamidronate, or
Evidence is insufficient to support the zoledronic acid.
efficacy of one bisphosphonate over the other.
Initiation of BP for Reasonable to consider BP treatment in women Recommendations for BPs are not restricted to patients
prevention of skeletal- with normal plain radiographs who demonstrate with osteolytic metastases.
related events bone destruction in other imaging.
Starting BPs in women with only an abnormal All women with breast cancer who have bone metastases
bone scan but without evidence of bone should be offered BPs.
destruction is not recommended.
An exception should be patients with a short expected
survival (that is, less than 6 months), who have well-
controlled bone pain.
Role in pain management The presence or absence of bone pain should In patients with bone metastases and pain, treatment with
not be a factor in initiating BPs. pamidronate, zoledronate, or clodronate may be a useful
adjunct to conventional measures for pain control.
Discontinuation Treatment with BPs to be continued until No evidence from clinical trials addresses the optimal
evidence appears of substantial decline in the duration of BP use.
patient’s performance status.BONE METASTASES MANAGEMENT
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TABLE II Overview of placebo-controlled trials of bisphosphonates in advanced breast cancer
Trial Bisphosphonate Dose Results
Paterson et al., 1993 9 Clodronate Oral, Reduced the event rate of vertebral fractures and deformity,
1600 mg daily and the combined event rate for all events.
Kristensen et al., 1999 8 Clodronate Oral, Reduced the number and significantly delayed the time to
400 mg twice daily first SRE.
Tubiana–Hulin et al., 2001 10 Clodronate Oral, Significantly delayed the time to first  bone event and
1600 mg daily significantly reduced pain intensity and analgesic use.
Hortobagyi et al., 1998 11 Pamidronate Intravenous, Reduced the incidence and delayed the onset of SREs.
90 mg every 3–4 weeks
Theriault et al., 1999 13 Pamidronate Intravenous, Reduced skeletal morbidity and the incidence of SREs and
90 mg every 4 weeks delayed the onset of SREs.
Lipton et al., 2000 14 Pamidronate Intravenous, Reduction in the percentage of patients with >1 SRE, median
90 mg every 3–4 weeks time to first SRE extended by nearly 6 months, and reduction
in the mean skeletal morbidity rate was found.
Hultborn et al., 1999 15 Pamidronate Intravenous, Significantly fewer SREs
60 mg every 4 weeks
Conte et al., 1996 16 Pamidronate Intravenous, Effective in delaying the time to progression of bone lesions.
45 mg every 3 weeks
Body et al., 2003 17 Ibandronate Intravenous, Significantly reduced the SMPR by 20% and extended the time
2 or 6 mg to first SRE.
every 3–4 weeks
Body et al., 2004 18 Ibandronate Orally, Significantly reduced the SMPR as compared with placebo in a
50 mg daily combined analysis.
Tripathy et al., 2004 19 Ibandronate Orally, Significantly reduced the SMPR as compared with placebo.
20 mg or 50 mg daily
Kohno et al., 2005 12 Zoledronic acid Intravenous, Significant multiple event analysis demonstrated a 44%
4 mg every 4 weeks reduction in the risk of developing a SRE.
SRE = skeletal-related event; SMPR = skeletal morbidity period rate.
TABLE III Overview of completed comparative trials of bisphosphonates in bone metastases
Trial Patients Bisphosphonate Primary outcome Conclusions
Jagdev et al., 2001 24 n=51 Clodronate: Use pain scores and NTX Pamidronate was more effective than
[various Oral, 1600 mg daily to compare efficacy clodronate with regard to pain control
primary cancers (group 1) of two schedules (p<0.01).
(22 breast)] Intravenous, of clodronate with No statistically significant difference in NTX
1500 mg loading, then intravenous pamidronate evident between groups.




90 mg every 3 weeks
(group 3)
Rosen et al., 2002 28 n=1648 Zoledronic acid: Use skeletal-related In subgroup of breast cancer
(myeloma and Intravenous infusion, events (SREs) and pain patients (n=1130), zoledronic acid had
breast cancer) 4 mg or 8 mg score to compare significant clinical benefit as compared
over 15 minutes efficacy of zoledronic with pamidronate:
Pamidronate: acid with that of prolonged time to first SRE,
Intravenous infusion, pamidronate 310 days vs. 174 days,  p=0.013;
90 mg over 2 hours and reduced incidence of SREs,
every 3–4 weeks mean 1.2 vs. 2.4 events per year, p=0.008.
NTX = N-terminal crosslinked type 1 collagen telopeptide.PETRUT et al.
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study, the proportion of patients with at least 1 SRE
was similar for zoledronic acid and pamidronate, but
zoledronic acid reduced by 20% the overall risk of
any skeletal complications developing (RR: 0.799; p =
0.025) 29. When phase III trial data are compared,
ibandronate and zoledronic acid seem to have simi-
lar efficacy 30. That hypothesis is currently being
tested in two large randomized phase III trials
(Table IV) 31,32.
2.2 Uncertainties About Bisphosphonate Use in
Clinical Practice
The evidence of clinical benefit from bisphosphonates
in breast cancer is overwhelming. Attention is now
concentrated on defining the optimal time to start
treatment, duration of treatment, and importantly,
predicting which patients are most likely to benefit
from either repeat bisphosphonate administration or
a switch to an alternative bisphosphonate 33 (Table V).
2.3 Which Patients Benefit Most from
Bisphosphonate Use?
Randomized controlled trials have shown that the ben-
eficial effects of bisphosphonates are time-dependent;
significant benefits were seen only after 6 months of
treatment 20. Therefore, looking at survival times for
patients with breast cancer is important before start-
ing them on bisphosphonate treatment.
A retrospective analysis involving 859 patients
who developed bone metastases from breast cancer
showed that, as compared with patients with bone
and visceral metastases, patients with disease con-
fined to the skeleton were most likely to develop a
SRE 34. The difference with regard to the development
of a SRE was probably attributable to the survival dif-
ference between the groups (median survival for pa-
tients with bone-only disease was 2.2 years as
compared with 5.5 months for patients with bone and
liver metastases). Patients with bone-only disease may
therefore benefit most from treatment with bisphos-
phonates, because they are most likely to live long
enough to experience the time-dependent benefits of
bisphosphonates 34. Notably, Canadian treatment
guidelines do not encourage the use of bisphospho-
nate treatment in patients with a life expectancy below
6 months and who are asymptomatic from their bone
metastases 3.
Along the same lines, most bisphosphonate tri-
als have enrolled a disproportionate number of pa-
tients with bone-only disease who, as a consequence
of their prolonged survival, are at greater risk of de-
veloping SREs than are patients with (for example)
TABLE V Summary of bisphosphonate use for metastatic bone disease in breast cancer patients
Placebo-controlled trials in breast cancer patients with bone metastases confirm significant reductions in the incidence and delay in the
occurrence of skeletal-related events (SREs) with bisphosphonate use.
Effects of bisphosphonates are time-dependent; in terms of reducing SREs, benefits begin to be identified after 6 months of treatment.
The benefits of bisphosphonate treatment in patients with poor prognosis are mostly unknown.
Which bisphosphonate to use as first-line therapy remains to be clarified. Evidence mainly supports the use of intravenous
aminobisphosphonates. However, clodronate can be offered to patients who are unable or unwilling to come to hospital for intrave-
nous treatment.
The absolute magnitude of bisphosphonate benefit and the who, when, and how long parameters of treatment remain unclear.
A switch to a more potent bisphosphonate (zoledronic acid or ibandronate) after either a SRE or bone metastasis progression during
treatment with a first-line bisphosphonate (clodronate or pamidronate) may offer better pain control.
TABLE IV Overview of ongoing comparative trials of bisphosphonates in metastatic breast cancer
Trial Patients (n) Bisphosphonate Duration of study Primary outcome Secondary outcomes
Southwest Oncology Group S0308 31
488 Ibandronate: 18 Months New skeletal- Time to first SRE, quality of life,
oral, 50 mg daily related event (SRE)
vs. overall survival, safety
Zoledronic acid:
intravenous,
4 mg every 4 weeks
Zoledronate versus Ibandronate Comparative Evaluation 32
1400 Ibandronate: 96 Weeks Multiple event analysis: Proportion of patients experiencing
oral, 50 mg daily of treatment SREs over 96 weeks new SRE, time to first event,
vs. with follow-up quality of life, safety
Zoledronic acid: for further 3 years
intravenous,
4 mg every 4 weeksBONE METASTASES MANAGEMENT
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visceral disease. Therefore, the magnitude of the ben-
efit seen in bisphosphonate trials probably exceeds
the benefit seen in clinical practice. Tables II and III
provide an overview of placebo-controlled trials and
comparative trials of bisphosphonate use in patients
with bone metastases.
Further prospective studies are needed to iden-
tify the subgroup of patients most likely to develop
SREs and therefore to benefit most from bisphospho-
nate treatment. In an attempt to develop a prediction
model, our group is currently analyzing baseline clini-
cal characteristics in 100 patients on bisphosphonates
at three cancer centers 35.
2.4 When Should Bisphosphonates Be Started in
Patients with Newly Diagnosed Bone
Metastases?
There is a paucity of data for optimal use of
bisphosphonates, mainly in regard to initiation and
treatment duration. According to ASCO guidelines, bis-
phosphonate therapy should be started in patients with
metastatic breast cancer who have imaging evidence
of lytic bone destruction. Furthermore, ASCO consid-
ers it “reasonable” to start intravenous bisphos-
phonates in breast cancer patients with an abnormal
bone scan despite normal plain radiographs, provided
that the patients are reporting concordant localized
pain. Intravenous bisphosphonate treatment is not rec-
ommended for asymptomatic patients with abnormal
bone scans whose plain radiographs are normal 4.
Canadian guidelines do not restrict the indications
for bisphosphonate therapy to patients with lytic bone
destruction on imaging 3. Despite these recommen-
dations, most trials suggest that, given the potential
of bisphosphonates to delay time to first SRE,
bisphosphonates should be started when bone me-
tastases are diagnosed, even when patients are asymp-
tomatic 21,27.
3. CHOOSING A BISPHOSPHONATE
Current Cancer Care Ontario guidelines advocate
starting patients with newly diagnosed bone me-
tastases on intravenous pamidronate or oral
clodronate as first-line treatment. In other North
American centers and in Europe, most patients with
breast cancer metastatic to bone are started on
zoledronic acid as first-line treatment 36.
Oral clodronate is approved for patients with
breast cancer, and it should be considered for patients
who cannot attend frequent clinic appointments or
who choose to decline intravenous therapy. The effi-
cacy of clodronate in preventing skeletal morbidity
has been shown in placebo–controlled clinical trials
of women with lytic bone disease (Table II) 8–10. How-
ever, in clinical practice, the potential for adverse
gastrointestinal effects and the very low absorption
rates (<5%) of oral clodronate even under ideal con-
ditions may contribute to poorer outcomes and poor
patient compliance 27.
Comparative trials have shown the superiority of
pamidronate over clodronate for pain control, and the
superiority of zoledronic acid over pamidronate for
delaying the first SRE and reducing the incidence of
SREs (Table III). Ongoing comparative studies are try-
ing to clarify which bisphosphonate is best to use in
clinical practice (Table IV). Interestingly, in one study,
patients receiving oral ibandronate after prior intra-
venous pamidronate significantly preferred the oral
regimen 30.
4. OPTIMAL DURATION OF
BISPHOSPHONATE TREATMENT
The ASCO guidelines recommend that bisphosphonate
treatment continue until there is evidence of a sub-
stantial decline in a patient’s general performance sta-
tus (Table I). A recent Canadian study confirmed that
90% of patients continue bisphosphonate treatment
until death, despite repeated SREs and bone progres-
sion 37. Criteria to guide response to bisphosphonate
therapy and the optimal and appropriate duration of
bisphosphonate administration are lacking. The deci-
sion to continue, stop, or switch to an alternative bis-
phosphonate remains empirical and based on personal
experience. Studies have shown that patients with skel-
etal disease progression and pain despite the use of
oral clodronate or intravenous pamidronate may
achieve an improvement in pain control and a reduc-
tion in levels of bone turnover markers after switch-
ing from pamidronate to zoledronic acid or to
ibandronate 30,38. Our group is starting a phase III trial
to define the role of, and best time to switch patients
to, a more potent bisphosphonate treatment after ei-
ther bone disease progression or development of a SRE
while on first-line bisphosphonate treatment 39.
Unfortunately, despite treatment with even the
most potent bisphosphonate (zoledronic acid), one
third of patients will develop further SREs within
2 years of initiating therapy. In addition, bisphospho-
nate side effects such as renal toxicity, nausea, vomit-
ing, flu-like symptoms, and osteonecrosis of the jaw
are becoming increasingly prominent concerns as the
use of these agents continues to increase 40,41. Further-
more, bisphosphonates are expensive agents; they have
a substantial impact on the oncology drug budget. In
a post hoc economic assessment of two multinational
trials, the cost of pamidronate was projected to greatly
exceed the cost savings associated with preventing a
SRE 40. However, a cost–utility analysis performed in
Canada of prophylactic pamidronate for prevention
of  SREs suggested that pamidronate offered breast can-
cer patients with bone metastases a substantial qual-
ity–adjusted benefit at a reasonable cost 42.
The existing cost-effectiveness data are difficult
to apply across different health care systems 43. Im-
portantly, maintaining patients on bisphosphonatePETRUT et al.
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treatment indefinitely has major financial implications
with unknown benefits. Pharmacoeconomic evalua-
tions should be therefore combined with clinical tri-
als to accurately predict the true cost of this supportive
treatment and, ultimately, to assess the optimal use
of these agents.
5. MARKERS OF BONE RESORPTION
In recent years, advances in understanding the mecha-
nism of bone metastases have led to the discovery of
several potential markers for dysregulation of bone
coupling. The most widely used markers are urinary
N-terminal crosslinked type 1 collagen telopeptide
(NTX) and C-terminal cross-linked type 1 telopep-
tide 44. Urinary NTX levels have been shown 45–47 to
predict
• occurrence of SREs in breast cancer patients with
bone metastases,
• response to bisphosphonates,
• pain scores, and
• patient outcomes.
Several studies have shown a strong correlation
between moderate (50–100 nmol/mmol creatinine)
and high (³ 100 nmol/mmol creatinine) levels of NTX
and the number of SREs or deaths (or both) in patients
with bone metastasis 44,48.
Furthermore, NTX seem to be valuable in assess-
ing how pain responds to bisphosphonates. In the
pooled analysis of phase III trials of zoledronic acid,
significant reductions in NTX were accompanied by
significant declines in bone-pain scores and lesser
increases in analgesic use at 96 weeks 48. Our own
group conducted a study with breast cancer patients
that showed a reduction in NTX levels after patients
on a second-generation bisphosphonate were
switched to a third-generation bisphosphonate after
development of a SRE or progressive bone disease.
The decline in NTX levels was an important predictor
for palliative pain response to both ibandronate 30 and
zoledronic acid 38.
Overall, the hope is that biochemical markers will
serve as adequate surrogates for further assessment
of bisphosphonate efficacy. However, given the lack
of sufficient, rigorous phase III data, current ASCO
guidelines advise against the use of biochemical
markers to monitor bisphosphonate treatment rou-
tinely 4. The role of bone markers in guiding bisphos-
phonate treatment is currently being tested in a large
National Cancer Research Institute–supported
phase III clinical trial in the United Kingdom (BISMARK,
n = 1400). In that trial, patients with breast cancer–
associated bone metastases are being treated with
zoledronic acid, either on a regular schedule of 4 mg
intravenously every 3–4 weeks, or as indicated by
NTX levels. The primary endpoint is development of
a SRE. Secondary endpoints include QOL, pain, anal-
gesic use, health economics, change in systemic
therapy, and survival.
6. NEW AGENTS TARGETING THE
MECHANISM OF BONE METASTASES
In metastatic bone disease, an imbalance occurs be-
tween the action of osteoblasts and that of osteoclasts,
with net bone loss resulting. A triad of molecules has
been shown to regulate the maturation, differentia-
tion, and survival of osteoclasts:
• receptor activator of nuclear factor kB (RANK),
• RANK ligand (RANKL), and
• osteoprotegerin (OPG) 49.
The RANKL/OPG ratio is significantly increased in
patients with severe osteolytic bone metastases.
Therefore, targeting the RANK–RANKL–OPG pathway is
a promising intervention for treating metastatic bone
disease, particularly among patients who are refrac-
tory to potent bisphosphonates 49.
Denosumab (AMG 162) is a human monoclonal
antibody that binds to and inhibits RANKL with high
affinity and specificity, mimicking the effect of en-
dogenous OPG. A recent phase II study of patients with
bone metastases showed that, as compared with pami-
dronate, denosumab is significantly more likely to
suppress urinary NTX. That study concluded that the
dose of 120 mg every 4 weeks is optimal for future
trials 50,51. Another randomized study of 255 bisphos-
phonate-naïve breast cancer patients with bone me-
tastasis found denosumab to be at least as effective
as intravenous bisphosphonates in reducing the risk
of SREs. A phase III trial comparing denosumab with
zoledronic acid is ongoing in patients with bone me-
tastases 51,52.
7. SUMMARY
Many systemic therapeutic options are available for
patients with bone metastases, with none being com-
pletely satisfactory. Bisphosphonates have become
the mainstay of practice, and their use in breast can-
cer patients with bone metastases is associated with
a significant reduction and delay in SREs and a reduc-
tion in bone pain. Despite the rapid integration of
bisphosphonates into standard clinical practice, many
uncertainties remain regarding their use: for example,
the optimal bisphosphonate agent and duration of
therapy, the most beneficial scheduling regimen, and
identification of the patients most likely to benefit
from bisphosphonate treatment.
Currently, Cancer Care Ontario guidelines advo-
cate for the use of intravenous pamidronate or oral
clodronate for patients with metastatic bone disease
secondary to breast cancer. Zoledronic acid is largely
reserved for clinical trials or for patients who are in-
tolerant to intravenous pamidronate. Meanwhile,BONE METASTASES MANAGEMENT
CURRENT ONCOLOGY—VOLUME 15, SUPPLEMENT 1
S56
elsewhere in North America and Europe, zoledronic
acid is first-line therapy for metastatic bone disease
among breast cancer patients.
Further research is merited to identify factors that
accurately predict the subgroups of patients at high-
est risk for developing bone metastases and subse-
quent complications and the patients that will benefit
most from bisphosphonate treatment. Markers of bone
turnover seem to hold the most promise for identify-
ing patients likely to benefit from bisphosphonate
treatment and for guiding the decision to discontinue
bisphosphonate therapy or to switch to an alternative
bisphosphonate. Finally, new osteoclast inhibitors are
currently under investigation, and these agents may
offer effective treatment options with reduced toxic-
ity for patients with bone metastases.
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